Drugs / LMP1 CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04657965 | Jan 2021 → Jan 2024 overdue | hematopoietic and lymphoid cell neoplasm, infectious disease | Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP1 CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04657965 ↗ |
| Modality | Cell therapy | “Each subject receive LMP1 CAR T-cells by intravenous infusion” NCT04657965 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT04657965 ↗ |